Page 3 - First Turn Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from First turn management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In First Turn Management Today - Breaking & Trending Today

Weiss Asset Management LP Has $142,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Weiss Asset Management LP Has $142,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Roivant Sciences Ltd , Deerfield Management Companylp Series , Citigroup Inc , Quarter For Roivant Sciences , Roivant Sciences Stock Performance , Roivant Sciences Company Profile , Wolfe Research , Deutsche Bank Aktiengesellschaft , Goldman Sachs Group , News Ratings For Roivant Sciences Daily , Roivant Sciences , Morgan Stanley , First Turn Management , Weiss Asset Management , Free Report , Asset Management , Turn Management , Bank Aktiengesellschaft , Truist Financial , Sciences Ltd , Visit Holdingschannel , Roivant Sciences Daily ,

Verona Pharma (NASDAQ:VRNA) Sets New 12-Month Low at $11.79

Verona Pharma plc (NASDAQ:VRNA – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $11.79 and last traded at $11.85, with a volume of 760873 shares trading hands. The stock had previously closed at $12.43. Analyst Ratings Changes VRNA has been the topic […] ....

United States , New Zealand General , New Zealand , Kathleena Rickard , Verona Pharma , Piper Sandler , Securities Exchange Commission , Clearbridge Investments , Wellington Management Group , American Century Companies Inc , Verona Pharma Company Profile , First Turn Management , Get Free Report , Pharma Trading Down , Exchange Commission , Capital Partners , Turn Management , Management Group , American Century Companies , Verona Pharma Daily ,

Millrace Asset Group Inc. Has $641,000 Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Millrace Asset Group Inc. trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 31.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,123 shares of the company’s stock after selling 3,759 shares during the period. Millrace Asset Group Inc.’s holdings in TransMedics […] ....

United States , Piper Sandler , David Weill , Transmedics Group Trading , Transmedics Group Inc , Transmedics Group , Transmedics Group Company Profile , Level Four Advisory Services , Securities Exchange Commission , News Ratings For Transmedics Group Daily , Millrace Asset Group Inc , Hsbc Holdings , Quarter For Transmedics Group , Dynamic Technology Lab Private Ltd , Morgan Stanley , A Davidson , Canaccord Genuity Group , First Turn Management , Millrace Asset Group , Free Report , Asset Group , Technology Lab Private Ltd , Four Advisory Services , Medics Group , Get Free Report , Director David Weill ,

Pier 88 Investment Partners LLC Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Pier 88 Investment Partners LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 1,170 shares of the company’s stock, valued at approximately $145,000. Other institutional investors have also modified their […] ....

United States , Kathryn Romano , Suma Krishnan , William Blair , Stifel Nicolaus , First Turn Management , Vanguard Group Inc , Krystal Biotech Company Profile , Investment Partners , Fred Alger Management , Securities Exchange Commission , Jennison Associates , Krystal Biotech Inc , Timessquare Capital Management , Krystal Biotech , Free Report , Turn Management , Alger Management , Square Capital Management , Biotech Trading Down , Get Free Report , Exchange Commission , Visit Holdingschannel , Krystal Biotech Daily ,

Cytokinetics (NASDAQ:CYTK) Price Target Cut to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target cut by Raymond James from $92.00 to $70.00 in a research note published on Thursday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other analysts have also weighed in on CYTK. Truist Financial reaffirmed a buy rating and […] ....

Johnt Henderson , Raymond James , Fady Ibraham Malik , Cytokinetics Incorporated , Norges Bank , Cytokinetics Company Profile , First Turn Management , Westfield Capital Management Co , Fisher Asset Management , Free Report , Moderate Buy , Get Free Report , Director John , Ibraham Malik , Turn Management , Capital Management , Cytokinetics Daily ,